Patents by Inventor Herman GRIFFIN

Herman GRIFFIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING MYOINTIMAL PROLIFERATION
    Publication number: 20220354933
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Application
    Filed: May 18, 2022
    Publication date: November 10, 2022
    Inventors: Yan YAN, Anumeha SHAH, Ashmita SAIGAL, Herman GRIFFIN, Susan Faas MCKNIGHT, Andre MAROZSAN, Kim ASKEW, Yvonne NITSCHKE, Frank RUTSCH
  • Methods of treating myointimal proliferation
    Patent number: 11364284
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: June 21, 2022
    Assignees: Inozyme Pharma, Inc., Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Yan Yan, Anumeha Shah, Ashmita Saigal, Herman Griffin, Susan Faas McKnight, Andre Marozsan, Kim Askew, Yvonne Nitschke, Frank Rutsch
  • EFFICACY OF AN ANTI-C5 ANTIBODY IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION IN SENSITIZED RECIPIENTS OF KIDNEY TRANSPLANT
    Publication number: 20210187054
    Abstract: A method for preventing AMR in a human kidney transplant recipient is provided. The method comprises: selecting a deceased donor; selecting a kidney transplant recipient; transplanting the kidney from the donor to the recipient; and administering a therapeutically effective dose of an anti-C5 antibody or fragment thereof to the recipient. The recipient is generally sensitized to the donor. Also provided is a method for treating AMR in a kidney transplant patient. The method comprises: selecting a kidney transplant patient having symptoms of AMR; and administering a therapeutically effective dose of an anti-C5 antibody or fragment thereof to the patient; wherein the dose of the anti-C5 antibody or fragment thereof reduces the symptoms of AMR.
    Type: Application
    Filed: October 27, 2020
    Publication date: June 24, 2021
    Inventors: Herman GRIFFIN, Xiang GAO, Rebecca VELEZ, Wei-Jian PAN
  • METHODS OF TREATING MYOINTIMAL PROLIFERATION
    Publication number: 20200306349
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 1, 2020
    Inventors: Yan YAN, Anumeha SHAH, Ashmita SAIGAL, Herman GRIFFIN, Susan Faas MCKNIGHT, Andre MAROZSAN, Kim ASKEW, Yvonne NITSCHKE, Frank RUTSCH
  • EFFICACY OF AN ANTI-C5 ANTIBODY IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION IN SENSITIZED RECIPIENTS OF A KIDNEY TRANSPLANT
    Publication number: 20190276524
    Abstract: This disclosure provides methods for reducing antibody mediated rejection (AMR) in a human kidney transplant recipient, comprising administering a therapeutically effective amount of an anti-C5 antibody, or antigen-binding fragment thereof, to the recipient in a phased dosing schedule following reperfusion of a kidney allograft, wherein the recipient is sensitized to a human living donor and wherein the recipient receives about two or more weeks of desensitization therapy prior to transplantation.
    Type: Application
    Filed: October 12, 2017
    Publication date: September 12, 2019
    Inventors: Herman GRIFFIN, Yi WANG, Rebecca FREY
  • EFFICACY OF AN ANTI-C5 ANTIBODY IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION IN SENSITIZED RECIPIENTS OF A KIDNEY TRANSPLANT
    Publication number: 20180311299
    Abstract: A method for preventing AMR in a human kidney transplant recipient is provided. The method comprises: selecting a deceased donor; selecting a kidney transplant recipient; transplanting the kidney from the donor to the recipient; and administering a therapeutically effective dose of an anti-C5 antibody or fragment thereof to the recipient. The recipient is generally sensitized to the donor. Also provided is a method for treating AMR in a kidney transplant patient. The method comprises: selecting a kidney transplant patient having symptoms of AMR; and administering a therapeutically effective dose of an anti¬ cs antibody or fragment thereof to the patient; wherein the dose of anti-C5 antibody or fragment thereof reduces the symptoms of AMR.
    Type: Application
    Filed: April 29, 2016
    Publication date: November 1, 2018
    Inventors: Herman GRIFFIN, Xiang GAO, Rebecca VELEZ, Wei-Jian PAN